Yourgene Health PLC Directors' dealing & warrant extension (4353Y)

TIDMYGEN

RNS Number : 4353Y

Yourgene Health PLC

09 May 2019

Yourgene Health plc

("Yourgene," the "Company")

Directors' dealing and warrant extension

Manchester, UK - 9 May 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified yesterday by Barry Hextall and Hayden Jeffreys, both directors of the Company, that they respectively purchased 89,551 and 222,348 ordinary shares of 0.10p each in the Company yesterday at an average price of 11.2 pence per ordinary share. The table below details each directors' shareholdings:

 
 Director           Shareholding         Number of ordinary   Shareholding   Ordinary 
                     prior to purchase    shares purchased     following      shares held 
                     of shares                                 purchase of    as percentage 
                                                               shares         of issued 
                                                                              voting share 
                                                                              capital 
 Barry Hextall           432,518               89,551           522,069          0.09% 
                   -------------------  -------------------  -------------  --------------- 
 Hayden Jeffreys            0                 222,348           222,348          0.04% 
                   -------------------  -------------------  -------------  --------------- 
 

Extension of warrant

Furthermore, the Company announces that it has agreed to extend the exercise period by a year of a warrant granted over 1,411,227 ordinary shares that was scheduled to expire on 13 June 2019.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 
For more information, please contact: 
Yourgene Health plc                      Tel: [phone] 
 Lyn Rees, Chief Executive Officer 
 Barry Hextall, Chief Financial Officer 
 Joanne Cross, Head of Marketing 
 [e-mail] 
Cairn Financial Advisers LLP (NOMAD)     Tel: [phone] 
 Liam Murray / James Caithie 
Stifel Nicolaus Europe Limited (Broker)  Tel: [phone] 
 Nicholas Moore / Matthew Balwat / Ben 
 Maddison 
Vigo Communications                      Tel: [phone] 
 Ben Simons / Fiona Henson / Antonia 
 Pollock 
 [e-mail] 
 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions.

Yourgene Health's first commercialised products are NIPT for Down's Syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.

Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1      Details of the person discharging managerial responsibilities/person 
         closely associated 
-----  -------------------------------------------------------------------------------- 
 a.     Name                                (i) Barry Hextall 
                                             (ii) Hayden Jeffreys 
                                      ------------------------------------------------- 
 2      Reason for notification 
       -----------------------------  ------------------------------------------------- 
 a.     Position/Status                     (i) Chief Financial Officer 
                                             (ii) Chief Operating Officer 
       -----------------------------  ------------------------------------------------- 
 b.     Initial notification/          Initial notification 
         Amendment 
                                      ------------------------------------------------- 
 3      Details of the issuer, emission allowance market participant, 
         auction platform, auctioneer or auction monitor 
 a.     Name                           Yourgene Health plc 
       ----------------------------- 
 b.     LEI                            213800UUIT8BZE7QEH33 
       -----------------------------  ------------------------------------------------- 
 4      Details of the transaction(s): section to be repeated for 
         (i) each type of instrument; (ii) each type of transaction; 
         (iii) each date; and (iv) each place where transactions have 
         been conducted 
-----  -------------------------------------------------------------------------------- 
 a.     Description of                 Ordinary shares of 0.10p each 
         the financial 
         instrument, type               ISIN: GB00BN31ZD89 
         of instrument 
 
         Identification 
         Code 
       -----------------------------  ------------------------------------------------- 
 b.     Nature of the                  Purchase of ordinary shares 
         transaction 
       -----------------------------  ------------------------------------------------- 
 
 c.     Price(s) and volume(s)              Price(s)            Volume(s) 
       -----------------------------       ------------------ 
                                                 (i) 11.5p           (i) 89,551 
                                                  (ii) 11.5p          (ii) 222,348 
                                           ------------------  -------------------- 
 
        Aggregated information 
 
         - Aggregated Volume                  311,899 
 
 d.      - Price                              11.5p 
       -----------------------------  ------------------------------------------------- 
 e.     Date of the transaction        8 May 2019 
       -----------------------------  ------------------------------------------------- 
 f.     Place of the transaction       London Stock Exchange 
       -----------------------------  ------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHKMGGKVRGGLZM

(END) Dow Jones Newswires

May 09, 2019 02:00 ET (06:00 GMT)